非心脏手术患者直接口服抗凝药与低分子肝素血栓预防的获益与危害:随机试验的系统评价与网络荟萃分析
该系统评价与网络荟萃分析纳入68项随机对照试验、45445例非心脏手术患者,比较直接口服抗凝药、低分子肝素(预防剂量或更高剂量)与无主动预防对症状性静脉血栓栓塞、症状性肺栓塞和大出血的影响。结果显示,低剂量低分子肝素(OR 0.33,95%CI 0.16-0.67)、高剂量低分子肝素(OR 0.19,95%CI 0.07-0.54)和直接口服抗凝药(OR 0.17,95%CI 0.07-0.41)均较无主动预防降低症状性静脉血栓栓塞,绝对风险差为每1000例1-100例,取决于基线风险(证据确定性中至高质量)。无一种主动药物降低症状性肺栓塞(证据确定性低至中等)。直接口服抗凝药和低分子肝素较无主动预防与大出血风险增加2-3倍相关(证据确定性中至高质量),高危患者绝对风险差高达每1000例50例。与低剂量低分子肝素相比,高剂量低分子肝素未降低症状性静脉血栓栓塞(OR 0.57,95%CI 0.26-1.27)但增加大出血(OR 1.87,95%CI 1.06-3.31);直接口服抗凝药降低症状性静脉血栓栓塞(OR 0.53,95%CI 0.32-0.89)且未增加大出血(OR 1.23,95%CI 0.89-1.69)。
要点
- 低剂量低分子肝素(OR 0.33,95%CI 0.16-0.67)、高剂量低分子肝素(OR 0.19,95%CI 0.07-0.54)和直接口服抗凝药(OR 0.17,95%CI 0.07-0.41)均较无主动预防降低症状性静脉血栓栓塞,绝对风险差为每1000例1-100例,取决于基线风险(证据确定性中至高质量)。
- 直接口服抗凝药和低分子肝素较无主动预防与大出血风险增加2-3倍相关(证据确定性中至高质量),高危患者绝对风险差高达每1000例50例。
- 与低剂量低分子肝素相比,高剂量低分子肝素未降低症状性静脉血栓栓塞(OR 0.57,95%CI 0.26-1.27)但增加大出血(OR 1.87,95%CI 1.06-3.31)。
- 与低剂量低分子肝素相比,直接口服抗凝药降低症状性静脉血栓栓塞(OR 0.53,95%CI 0.32-0.89)且未增加大出血(OR 1.23,95%CI 0.89-1.69)。
- 无一种主动药物降低症状性肺栓塞(证据确定性低至中等)。
适用人群与场景
- 接受非心脏手术的成人(纳入68项随机对照试验,包括51项骨科、10项普外科、4项妇科、2项胸科和1项泌尿外科手术,共45445例患者)。
研究设计与关键结果
- 研究设计:系统评价与网络荟萃分析,纳入68项随机对照试验(51项骨科、10项普外科、4项妇科、2项胸科、1项泌尿外科手术),共45445例患者。
- 与无主动预防相比,低剂量低分子肝素(OR 0.33,95%CI 0.16-0.67)、高剂量低分子肝素(OR 0.19,95%CI 0.07-0.54)和直接口服抗凝药(OR 0.17,95%CI 0.07-0.41)均降低症状性静脉血栓栓塞,绝对风险差为每1000例1-100例,取决于基线风险(证据确定性中至高质量)。
- 无一种主动药物降低症状性肺栓塞(证据确定性低至中等)。
- 直接口服抗凝药和低分子肝素较无主动预防与大出血风险增加2-3倍相关(证据确定性中至高质量),高危患者绝对风险差高达每1000例50例。
- 与低剂量低分子肝素相比,高剂量低分子肝素未降低症状性静脉血栓栓塞(OR 0.57,95%CI 0.26-1.27)但增加大出血(OR 1.87,95%CI 1.06-3.31)。
- 与低剂量低分子肝素相比,直接口服抗凝药降低症状性静脉血栓栓塞(OR 0.53,95%CI 0.32-0.89)且未增加大出血(OR 1.23,95%CI 0.89-1.69)。
证据类型、等级与局限
- 证据类型:系统评价与网络荟萃分析(随机对照试验)。
- 证据确定性:症状性静脉血栓栓塞结局为中至高质量;症状性肺栓塞结局为低至中等质量;大出血结局为中至高质量(GRADE评估)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,直接口服抗凝药和低分子肝素较无主动预防降低静脉血栓栓塞但可能以相似程度增加大出血;直接口服抗凝药预防症状性静脉血栓栓塞可能优于预防性低分子肝素。
指南或共识出处
- PROSPERO注册号CRD42018106181。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To systematically compare the effect of direct oral anticoagulants and low molecular weight heparin for thromboprophylaxis on the benefits and harms to patients undergoing non-cardiac surgery.
DESIGN: Systematic review and network meta-analysis of randomised controlled trials.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL), up to August 2021.
REVIEW METHODS: Randomised controlled trials in adults undergoing non-cardiac surgery were selected, comparing low molecular weight heparin (prophylactic (low) or higher dose) with direct oral anticoagulants or with no active treatment. Main outcomes were symptomatic venous thromboembolism, symptomatic pulmonary embolism, and major bleeding. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for network meta-analyses. Abstracts and full texts were screened independently in duplicate. Data were abstracted on study participants, interventions, and outcomes, and risk of bias was assessed independently in duplicate. Frequentist network meta-analysis with multivariate random effects models provided odds ratios with 95% confidence intervals, and GRADE (grading of recommendations, assessment, development, and evaluation) assessments indicated the certainty of the evidence.
RESULTS: 68 randomised controlled trials were included (51 orthopaedic, 10 general, four gynaecological, two thoracic, and one urological surgery), involving 45 445 patients. Low dose (odds ratio 0.33, 95% confidence interval 0.16 to 0.67) and high dose (0.19, 0.07 to 0.54) low molecular weight heparin, and direct oral anticoagulants (0.17, 0.07 to 0.41) reduced symptomatic venous thromboembolism compared with no active treatment, with absolute risk differences of 1-100 per 1000 patients, depending on baseline risks (certainty of evidence, moderate to high). None of the active agents reduced symptomatic pulmonary embolism (certainty of evidence, low to moderate). Direct oral anticoagulants and low molecular weight heparin were associated with a 2-3-fold increase in the odds of major bleeding compared with no active treatment (certainty of evidence, moderate to high), with absolute risk differences as high as 50 per 1000 in patients at high risk. Compared with low dose low molecular weight heparin, high dose low molecular weight heparin did not reduce symptomatic venous thromboembolism (0.57, 0.26 to 1.27) but increased major bleeding (1.87, 1.06 to 3.31); direct oral anticoagulants reduced symptomatic venous thromboembolism (0.53, 0.32 to 0.89) and did not increase major bleeding (1.23, 0.89 to 1.69).
CONCLUSIONS: Direct oral anticoagulants and low molecular weight heparin reduced venous thromboembolism compared with no active treatment but probably increased major bleeding to a similar extent. Direct oral anticoagulants probably prevent symptomatic venous thromboembolism to a greater extent than prophylactic low molecular weight heparin.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018106181.
参考来源
- Marcucci M, Etxeandia-Ikobaltzeta I, Yang S, et al. Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials. BMJ. 2022. PMID: 35264372. doi:10.1136/bmj-2021-066785
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。